Rite Aid Corporation ( RAD Quick Quote RAD - Free Report) rallied more than 17% after the close of trading session on Dec 17, following its impressive third-quarter fiscal 2021 results. Strength in Elixir, rise in pharmacy sales and robust online performance aided quarterly results. Further, it remains on track with its RxEvolution strategy. Additionally, cost-cutting actions contributed to quarterly growth. In the past three months, shares of this company have surged 49.4% compared with the industry’s 13.7% decline. Q3 in Detail
The company delivered adjusted earnings of 40 cents per share, which came ahead of the Zacks Consensus Estimate of a loss of a penny. However, the bottom line declined 25.9% from the year-ago quarter’s figure of 54 cents. This might be due to weak adjusted EBITDA and elevated costs related to lease termination and impairment, which more than offset reduced interest expenses and contribution from the sale of its distribution center at Perryman, MD.
Revenues grew 12% to $6,117 million and surpassed the Zacks Consensus Estimate of $5,846 million. This uptick was mainly due to solid performance in the Retail Pharmacy and Pharmacy Services segments. Apart from these, the company’s top line gained from strength in Elixir, driven by 29% increase in Medicare Part D memberships which more than offset drab acute script volumes. During the quarter, Retail Pharmacy segment revenues grew 5.1% due to higher same-store sales. In the Pharmacy Services segment, revenues rose 29.2% owing to a rise in Medicare Part D membership. Retail pharmacy same-store sales advanced 4.3%, thanks to a 6.1% rise in pharmacy sales. Excluding cigarettes and tobacco products, front-end same-store sales rose 0.3% on the back of growth in certain product categories including immunity, first aid and paper products. Further, prescription count at same-store sales, adjusted to 30-day equivalents, grew 3.1% on the back of a rise in maintenance prescriptions and increased home deliveries, which were somewhat offset by lower acute prescription count to the tune of 1.9%. Online revenues skyrocketed 225% year over year in the quarter under review on the back of revamped website and mobile app. Also, strategic partnerships with Amazon ( AMZN Quick Quote AMZN - Free Report) for the sale of its products, and Instacart for home delivery, acted as upsides. During the reported quarter, adjusted EBITDA fell 13.1% year over year to $137.4 million, driven by higher revenues and lower costs. Meanwhile, adjusted EBITDA margin contracted 60 bps at 2.5% in the quarter under review. In addition, SG&A expenses grew 1.9% year over year to $1,156.4 million. Rite Aid Corporation Price, Consensus and EPS Surprise Financial Status
Rite Aid ended the quarter with cash and cash equivalents of approximately $50.8 million, long-term debt (net of current maturities) of $3,200.6 million and total shareholders’ equity of $610.5 million.
Further, the company generated cash from operating activities of $222.7 million in fiscal third quarter. Rite Aid boasts liquidity of roughly $1.6 billion, which is likely to help it stay afloat during the pandemic. Business Development
During the quarter, Rite Aid launched its new brand and logo. Some other notable efforts include improving product mix, revamping more than 700 stores, launching three new Store of the Future prototypes and integrating two legacy PBMs. Further, the company redesigned its website and mobile app. Also, it is on track to launch the first phase of its new member portal at Elixir. Apart from these, Rite Aid’s pilot stores have been performing well in terms of sales and margins, following which it now intends to rollout the next phase of these stores in the fiscal fourth quarter.
Management has already reached the milestone of 1 million COVID-19 tests in partnership with the U.S. Department of Health and Human Services. Going ahead, it is joining forces with the CDC to distribute vaccines for the second phase of the rollout. Fiscal 2021 Outlook
This Zacks Rank #3 (Hold) stock has revised its fiscal 2021 guidance, keeping in mind lower Medicare Part D membership, the demand for flu immunizations, enhanced pharmacy network management at Elixir and cost savings. The company now expects revenues to be $23.9-$24.2 billion with same-store sales growth of 3.5-4.5%. The bottom line is envisioned between 45-85 cents. Moreover, adjusted EBITDA is expected to be between $490 to $520 million. Capital expenditure is anticipated to be roughly $325 million. Also, it expects free cash flow of $50-$100 million.
Stocks to Consider Target Corporation ( TGT Quick Quote TGT - Free Report) has an impressive long-term earnings growth rate of 8.5% and a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here The TJX Companies ( TJX Quick Quote TJX - Free Report) , which presently carries a Zacks Rank #2, has an expected long-term earnings growth rate of 10.5%. 5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >>